Abstract
BackgroundPanitumumab is the first human combinatorial antibody for the treatment of metastatic colorectal carcinoma. Dermatologic toxicity of all grades occurs in more than 90% of patients. However, there are few reports of purpura induced by anti-epidermal growth factor receptor antibody. Renal failure is also uncommon as an adverse event of anti-epidermal growth factor receptor antibody.Case presentationA 67-year-old Japanese man with advanced colon cancer received monotherapy with panitumumab. General malaise, bilateral edema of his legs, and bilateral purpura of his forearms developed 2 days after the second cycle of panitumumab. A skin biopsy was performed to evaluate the purpuric lesions on his left leg and leukocytoclastic vasculitis was diagnosed. Blood tests showed grade III acute renal failure with a blood urea nitrogen level of 33.8 mg/dL and a creatinine level of 3.10 mg/dL.ConclusionsThis is the first reported case of leukocytoclastic vasculitis followed by purpura and acute renal failure associated with panitumumab.
Highlights
Panitumumab is the first human combinatorial antibody for the treatment of metastatic colorectal carcinoma
We describe a patient with advanced colon cancer with bilateral edema of the legs and bilateral purpura noted 2 days after a second cycle of panitumumab
This is the first reported case of Leukocytoclastic vasculitis (LCV) followed by purpura and acute renal failure associated with panitumumab
Summary
Panitumumab is a fully humanized antibody for the treatment of RAS wild-type metastatic colorectal carcinoma (mCRC). We describe a patient with advanced colon cancer with bilateral edema of the legs and bilateral purpura noted 2 days after a second cycle of panitumumab. Considering that our patient had already been treated with the combination chemotherapies FOLFIRI and mFOLFOX-6 and the wild-type RAS status of his primary tumor, treatment with bi-weekly panitumumab monotherapy (500 mg/m2) was initiated on July 20, 2010 He had no adverse events after the initial course of panitumumab. Leg swelling, and skin rash developed 2 days after the second cycle of panitumumab (2 weeks after the initial dose), and around August 18 the symptoms intensified. He had neither joint pain nor abdominal pain during the period.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
